Document Detail

Cost-effectiveness of spironolactone in patients with severe heart failure.
MedLine Citation:
PMID:  12930056     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Management of heart failure is estimated to consume between 1% and 2% of total healthcare resources with hospital admissions accounting for up to 70% of this. The ability of the aldosterone antagonist spironolactone to reduce hospital admission rates by 35% would be expected to prove cost-effective. AIM: To determine the cost-effectiveness of spironolactone when added to standard therapy in patients with severe chronic heart failure. METHODS: A Markov model of chronic heart failure was constructed using Treeage software. Irish cost data were incorporated into the model. RESULTS: The incremental cost-effectiveness ratio (ICER) for spironolactone therapy was Euro 466 per life year gained (LYG). Sensitivity analysis demonstrated an ICER range of Euro 75 to Euro 1,136 per LYG. CONCLUSION: This economic evaluation suggests that the addition of spironolactone to standard therapy for patients with severe chronic heart failure is not only safe and effective, but is highly cost-effective in the Irish healthcare setting.
L Tilson; B McGowan; M Ryan; M Barry
Related Documents :
20631986 - The rage axis in systemic inflammation, acute lung injury and myocardial dysfunction: a...
19514646 - Marine polyunsaturated fatty acids in heart failure. are the theoretical benefits match...
25215156 - Clinical and procedural predictors of no-reflow in patients with acute myocardial infar...
14988626 - Clinical trials in the surgical management of congestive heart failure: surgical ventri...
24460586 - Evaluation of stroke volume and ventricular mass in a fetal heart model: a novel four-d...
18091646 - A review of factors contributing to health related quality of life achieved with cardia...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Irish journal of medical science     Volume:  172     ISSN:  0021-1265     ISO Abbreviation:  Ir J Med Sci     Publication Date:    2003 Apr-Jun
Date Detail:
Created Date:  2003-08-21     Completed Date:  2003-12-11     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  7806864     Medline TA:  Ir J Med Sci     Country:  Ireland    
Other Details:
Languages:  eng     Pagination:  70-2     Citation Subset:  IM    
National Centre for Pharmacoeconomics, St James's Hospital, Dublin, Ireland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aldosterone Antagonists / economics*,  therapeutic use*
Cost-Benefit Analysis
Costs and Cost Analysis
Heart Failure / drug therapy*
Markov Chains
Spironolactone / economics*,  therapeutic use*
Reg. No./Substance:
0/Aldosterone Antagonists; 52-01-7/Spironolactone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Anticonvulsant use in elderly patients in long-term care units.
Next Document:  Late onset Alzheimer's disease and apolipoprotein association in the Irish population: relative risk...